Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome

Running, not enrolling · Phase 2

Conditions studied: Obstructive Sleep Apnea, Down Syndrome

In brief

This is an open-label study of the combination of atomoxetine and oxybutynin (ato-oxy) in children with Down syndrome and obstructive sleep apnea (OSA) documented by polysomnography (PSG). Participants will receive ato-oxy for 6 months. Ato-oxy dose will be 5 mg oxybutynin and 0.5mg/kg/day (max 40 mg) atomoxetine. Dosing of the study treatment will occur approximately 30 minutes prior to bedtime. Participants who withdraw from the study will not be replaced. Study participants will undergo eligibility screening that will include an initial screening to determine whether non- PSG enrollment criteria are met, followed by a 1 night in-lab PSG and health-related quality of life (HRQOL) and cognitive assessment for participants who qualify based on non-PSG criteria. For participants who are eligible and enroll in the study, the screening PSG night will serve as the baseline measure for apnea hypopnea index (AHI) and other PSG endpoints. On the final night of dosing for ato-oxy participants will return for inpatient PSG and health-related quality of life assessment and cognitive assessment. The primary efficacy endpoint is the change in obstructive AHI from baseline.

Key facts

Study ID

NCT05933603

Run by

University of Arizona

People needed

36

Starts

2023-09-29

Expected to finish

2026-06-01

Last updated by the study team

2026-04-07

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female participants between 6 to 17 years of age, inclusive, at the Screening Visit.
• Known diagnosis of Down syndrome (trisomy 21, but not translocation or mosaicism)

You may not qualify if…

• Presence of central sleep apnea on polysomnography (central AHI ≥ 5)
• Currently using and adherent to positive airway pressure therapy (>4 hours per night for 70% of nights in the past 30 days based on device download or parent report)
• Monoamine oxidase inhibitor use
• Urinary retention
• Prematurity < 32 weeks estimated gestational age
• Seizure disorder
• Untreated or inadequately treated hypothyroidism
• Significant traumatic brain injury
• Congenital heart disease and not cleared to participate by the patient's cardiologist
• History of current, untreated depression
• History of liver disease
• 3+ or greater tonsillar hypertrophy
• Positive urine pregnancy test
• Hypoxemia independent of respiratory events on baseline polysomnography (≥5 minutes with oxygen saturation <90%)
• Presence of central sleep apnea on baseline polysomnography (central AHI ≥ 5)
• Absence of OSA defined as total AHI <5 on baseline polysomnography

Where it is running

• University of Arizona — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.